Qun Li

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

M. Sasamata, Y. Uchiyama, Hiroshi Tomiyama, 2014, European journal of pharmacology.

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Yun-xia Tang, Linghang Wang, Siyuan Yang, 2022, Pharmacogenomics and personalized medicine.

Effects of sodium‐glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin‐induced type 1 diabetic rats

M. Sasamata, Atsushi Noda, Rumi Kihara, 2014, The Journal of pharmacy and pharmacology.

Elucidating the Gene Signatures and Immune Cell Types in HIV-Infected Immunological Non-Responders by Bioinformatics Analyses

Fujie Zhang, Junyan Han, Hongxin Zhao, 2022, International journal of general medicine.

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

M. Sasamata, Atsushi Noda, Rumi Kihara, 2013, European journal of pharmacology.